Jeffrey J. Rade

Jeffrey J. Rade

Auto-generated profile, based on publicly available information

Jeffrey J. Rade

Division of Cardiovascular Medicine, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2021 in Circulation Research
Verified
Journal Article
Closed access
PDF file
MKMilka Koupenova
Milka Koupenova
HCHeather A. Corkrey
Heather A. Corkrey
OVOlga Vitseva
Olga Vitseva
KTKahraman Tanriverdi
Kahraman Tanriverdi
MSMohan Somasundaran
Mohan Somasundaran
JFJane E. Freedman
Jane E. Freedman
Rationale: Coronavirus disease 2019 (COVID-19) is characterized by increased incidence of microthrombosis with hyperactive platelets sporadically containing viral RNA. It is unclear if SARS-CoV-2 (severe acute respiratory syndrome, corona virus-2) directly alters platelet activation or if these changes are a reaction to infection-mediated global inflammatory alterations. Importantly, the direct effect of SARS-CoV-2 on platelets has yet to be studied. Objective: To characterize the direct SARS-CoV-2–platelet interactions using in vitro studies with purified infectious virions and samples from infected patients. Methods and Results: Platelet RNA analyzed by ARTIC v3 sequencing for SARS-CoV-2 showed presence of fragmented viral genome in all patients with COVID-19. Immunofluorescent imaging of platelets from patients with COVID-19 confirmed presence of SARS-CoV-2 proteins, whereas there was no detection of viral RNA by real-time quantitative polymerase chain reaction. Transmission electron microscopy of platelets incubated with purified SARS-CoV-2 virions demonstrated rapid internalization and digestion leading to distinct morphological changes and resulted in a release of extracellular vesicles. Interactions between SARS-CoV-2 and platelets occurred with or without ACE (angiotensin-converting enzyme) 2 presence as measured by immunofluorescence. Transmission electron microscopy showed that SARS-CoV-2 virions became internalized when they were attached to microparticles, bypassing the need for ACE2. Enrichment analysis of platelet transcriptome from patients with acute COVID-19, compared with those with clinical thrombosis, suggested upregulation of pathways related to virally mediated cell death, specifically necroptosis and apoptosis. Platelets incubated with infectious virus appeared to undergo cell death in 30 minutes postincubation as assessed by transmission electron microscopy and platelets from patients with COVID-19 showed evidence of increased markers of apoptosis and necroptosis by Western blot. Immunofluorescence confirmed colocalization of SARS-CoV-2 with phospho-MLKL (mixed lineage kinase domain-like pseudokinase) and caspase 3 on nonpermeabilized platelets in vitro and in COVID-19 platelets. Conclusions: Platelets internalize SARS-CoV-2 virions, directly or attached to microparticles, and viral internalization leads to rapid digestion, programmed cell death, and extracellular vesicle release. During COVID-19, platelets mediate a rapid response to SARS-CoV-2 and this response can contribute to dysregulated immunity and thrombosis.

15 May 2005 in Blood
Verified
Journal Article
Closed access
PDF file
RSRichard H. Sohn
Richard H. Sohn
CDClayton B. Deming
Clayton B. Deming
DJDavid C. Johns
David C. Johns
HCHunter C. Champion
Hunter C. Champion
CBCe Bian
Ce Bian
JRJeffrey J. Rade
Jeffrey J. Rade
Inflammation and thrombosis are increasingly recognized as interrelated biologic processes. Endothelial cell expression of thrombomodulin (TM), a key component of the anticoagulant protein C pathway, is potently inhibited by inflammatory cytokines. Because the mechanism underlying this effect is largely unknown, we investigated a potential role for the inflammatory transcription factor nuclear factor-kappa B (NF-κB). Blocking NF-κB activation effectively prevented cytokine-induced down-regulation of TM, both in vitro and in a mouse model of tumor necrosis factor-α (TNF-α)–mediated lung injury. Although the TM promoter lacks a classic NF-κB consensus site, it does contain tandem Ets transcription factor binding sites previously shown to be important for both constitutive TM gene expression and cytokine-induced repression. Using electrophoretic mobility shift assay and chromatin immunoprecipitation, we found that multiple Ets species bind to the TNF-α response element within the TM promoter. Although cytokine exposure did not alter Ets factor binding, it did reduce binding of p300, a coactivator required by Ets for full transcriptional activity. Overexpression of p300 also prevented TM repression by cytokines. We conclude that NF-κB is a critical mediator of TM repression by cytokines. Further evidence suggests a mechanism involving competition by NF-κB for limited pools of the transcriptional coactivator p300 necessary for TM gene expression.

1 October 2013 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
NKN. Kakouros
N. Kakouros
TKT. S. Kickler
T. S. Kickler
KLK. M. Laws
K. M. Laws
JRJ. J. Rade
J. J. Rade

1 December 2020 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Open access
PDF file
AKAthan Kuliopulos
Athan Kuliopulos
PBPaul A Bliden
Paul A Bliden
JRJeffrey J. Rade
Jeffrey J. Rade
CKCarey D. Kimmelstiel
Carey D. Kimmelstiel
STSusan E. Turner
Susan E. Turner
OIon behalf of the TRIP-PCI Investigators
on behalf of the TRIP-PCI Investigators
Objective: Arterial thrombosis leading to ischemic injury worsens the prognosis of many patients with cardiovascular disease. PZ-128 is a first-in-class pepducin that reversibly inhibits PAR1 (protease-activated receptor 1) on platelets and other vascular cells by targeting the intracellular surface of the receptor. The TRIP-PCI (Thrombin Receptor Inhibitory Pepducin in Percutaneous Coronary Intervention) trial was conducted to assess the safety and efficacy of PZ-128 in patients undergoing cardiac catheterization with intent to perform percutaneous coronary intervention. Approach and Results: In this randomized, double-blind, placebo-controlled, phase 2 trial, 100 patients were randomly assigned (2:1) to receive PZ-128 (0.3 or 0.5 mg/kg), or placebo in a 2-hour infusion initiated just before the start of cardiac catheterization, on top of standard oral antiplatelet therapy. Rates of the primary end point of bleeding were not different between the combined PZ-128 doses (1.6%, 1/62) and placebo group (0%, 0/35). The secondary end points of major adverse coronary events at 30 and 90 days did not significantly differ but were numerically lower in the PZ-128 groups (0% and 2% in the PZ-128 groups, 6% and 6% with placebo, p=0.13, p=0.29, respectively). In the subgroup of patients with elevated baseline cardiac troponin I, the exploratory end point of 30-day major adverse coronary events + myocardial injury showed 83% events in the placebo group versus 31% events in the combined PZ-128 drug groups, an adjusted relative risk of 0.14 (95% CI, 0.02–0.75); P =0.02. Conclusions: In this first-in-patient experience, PZ-128 added to standard antiplatelet therapy appeared to be safe, well tolerated, and potentially reduced periprocedural myonecrosis, thus providing the basis for further clinical trials. Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT02561000.

1 June 2022 in JACC
Verified
Journal Article
Closed access
JRJeffrey J. Rade
Jeffrey J. Rade
BBBruce A. Barton
Bruce A. Barton
RVRamachandran S. Vasan
Ramachandran S. Vasan
SKShari S. Kronsberg
Shari S. Kronsberg
VXVanessa Xanthakis
Vanessa Xanthakis
TKThomas A. Kickler
Thomas A. Kickler

16 October 2012 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
MOM. T. Olson
M. T. Olson
TKT. S. Kickler
T. S. Kickler
JLJ. A. Lawson
J. A. Lawson
RMR. C. Mclean
R. C. Mclean
JJJ. Jani
J. Jani
JRJ. J. Rade
J. J. Rade